Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals

[1]  J. Cairns,et al.  Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation , 2016, Journal of hepatology.

[2]  N. Luhmann,et al.  Human rights and access to hepatitis C treatment for people who inject drugs. , 2015, The International journal on drug policy.

[3]  F. Altice,et al.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. , 2015, The International journal on drug policy.

[4]  T. Swan,et al.  A path to eradication of hepatitis C in low- and middle-income countries. , 2015, Antiviral research.

[5]  D. Semela,et al.  “Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis , 2014, BMC Infectious Diseases.

[6]  G. Dore,et al.  Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. , 2013, Drug and alcohol dependence.

[7]  V. Bencko,et al.  Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review , 2013, Patient preference and adherence.

[8]  L. Taylor,et al.  Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  N. Bath,et al.  Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  P. Mateu-Gelabert,et al.  Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study , 2013, Harm Reduction Journal.

[11]  S. Sockalingam,et al.  Psychiatric treatment considerations with direct acting antivirals in hepatitis C , 2013, BMC Gastroenterology.

[12]  T. Rhodes,et al.  Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors , 2013, Harm Reduction Journal.

[13]  T. Rhodes,et al.  Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting. , 2013, Social science & medicine.

[14]  C. Stedman,et al.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.

[15]  T. Pilot‐Matias,et al.  Exploratory study of oral combination antiviral therapy for hepatitis C. , 2013, The New England journal of medicine.

[16]  Soo Downe,et al.  Why Do Women Not Use Antenatal Services in Low- and Middle-Income Countries? A Meta-Synthesis of Qualitative Studies , 2013, PLoS medicine.

[17]  C. Pariante,et al.  Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. , 2012, Journal of hepatology.

[18]  Carrie D. Patnode,et al.  Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness , 2012 .

[19]  Nancy Glass,et al.  Global burden of hepatitis C: considerations for healthcare providers in the United States. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. McKevitt,et al.  Lay perspectives on hypertension and drug adherence: systematic review of qualitative research , 2012, BMJ : British Medical Journal.

[21]  T. Wong,et al.  New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials , 2012, International journal of clinical practice.

[22]  R. Monina Klevens,et al.  The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.

[23]  J. Grebely,et al.  Management of HCV and HIV infections among people who inject drugs. , 2011, Current opinion in HIV and AIDS.

[24]  A Russell Localio,et al.  Relationship Between Adherence to Hepatitis C Virus Therapy and Virologic Outcomes , 2011, Annals of Internal Medicine.

[25]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[26]  M. Rutter,et al.  What can we learn from patients with heart failure about exercise adherence? A systematic review of qualitative papers. , 2011, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[27]  Jean-Michel Pawlotsky,et al.  Treatment failure and resistance with direct‐acting antiviral drugs against hepatitis C virus , 2011, Hepatology.

[28]  J. Lambert,et al.  Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. , 2010, AIDS patient care and STDs.

[29]  C. Treloar,et al.  Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals , 2010, Journal of viral hepatitis.

[30]  D. Shepard,et al.  Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward , 2010, The Lancet.

[31]  C. Treloar,et al.  Hepatitis C treatment in pharmacotherapy services: increasing treatment uptake needs a critical view. , 2009, Drug and alcohol review.

[32]  Kenneth A. Harris,et al.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. , 2009, Journal of substance abuse treatment.

[33]  M. Harris.  Relapse to Injecting Drug Use: A Hepatitis C Treatment Concern , 2009 .

[34]  Margaret Hellard,et al.  High incidence of hepatitis C virus reinfection in a cohort of injecting drug users , 2008, Hepatology.

[35]  F. Negro,et al.  Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients , 2008, Journal of viral hepatitis.

[36]  C. Treloar,et al.  Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. , 2008, Australian health review : a publication of the Australian Hospital Association.

[37]  N. Lintzeris,et al.  The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users , 2008, Harm reduction journal.

[38]  H. Hagan,et al.  Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. , 2008, The International journal on drug policy.

[39]  K. Morrow,et al.  A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV. , 2008, AIDS patient care and STDs.

[40]  P. Sainsbury,et al.  Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. , 2007, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[41]  Carla Treloar,et al.  The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection. , 2007, The International journal on drug policy.

[42]  J. Kaldor,et al.  Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. , 2007, The International journal on drug policy.

[43]  S. Lewin,et al.  Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research , 2007, PLoS medicine.

[44]  M. Grypdonck,et al.  Adherence in antiretroviral therapy: a review of qualitative studies , 2007, AIDS.

[45]  I. Buchan,et al.  Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006, PLoS medicine.

[46]  P. Thuras,et al.  Integrated Psychiatric/Medical Care in a Chronic Hepatitis C Clinic: Effect on Antiviral Treatment Evaluation and Outcomes , 2006, The American Journal of Gastroenterology.

[47]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[48]  C. Treloar,et al.  The Experience of Interferon-Based Treatments for Hepatitis C Infection , 2005, Qualitative health research.

[49]  D. D. Jarlais,et al.  Residential Substance User Treatment Programs as Venues for HCV Pharmacological Treatment: Client and Staff Perspectives , 2005, Substance use & misuse.

[50]  L. Copeland.  The drug user's identity and how it relates to Being Hepatitis C antibody positive: a qualitative study , 2004 .

[51]  for the Hiv/aids Treatment Adherence, Health Outco,et al.  Literature on integrated HIV care: a review , 2004, AIDS care.

[52]  C. Treloar,et al.  The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics. , 2012, Social science & medicine.

[53]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[54]  C. Day,et al.  Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users. , 2009, Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals.